Author/Authors :
Song, Steven Department of Medicine - SUNY Downstate Medical Center, Brooklyn, NY, USA , Cook, Joselle Department of Medicine - SUNY Downstate Medical Center, Brooklyn, NY, USA , Goulbourne, Clive Department of Medicine - SUNY Downstate Medical Center, Brooklyn, NY, USA , Meade, Matthew Department of Medicine - SUNY Downstate Medical Center, Brooklyn, NY, USA , Salciccioli, Louis Division of Cardiovascular Medicine - SUNY Downstate Medical Center, Brooklyn, NY, USA , Lazar, Jason Division of Cardiovascular Medicine - SUNY Downstate Medical Center, Brooklyn, NY, USA
Abstract :
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of
nonvalvular atrial fibrillation.The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated
since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer
patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of
NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to
dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy
